Director Share Purchases

RNS Number : 2849R

Alliance Pharma PLC

26 June 2020

 

26 June 2020

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Director Share Purchases

Alliance Pharma plc (AIM: APH), the international healthcare group, was notified on 23 June 2020 that on 23 June 2020 David Cook, Chairman of the Company, purchased 63,879 ordinary shares of 1.0p each in the Company ("Ordinary Shares") at a price of 77.7 pence per share , and his spouse, Katharine Cook, also purchased 63,879 Ordinary Shares on the same date at 77.7   pence per share.

Following these transactions, David and Katharine Cook's total beneficial interest in the Company is 234,129 Ordinary Shares, representing approximately 0.04% of the Company's issued share capital.

The notification of dealing forms for Persons Discharging Managerial Responsibility ("PDMR") and Person Closely Associated ("PCA") can be found below. The information contained within this announcement is made in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	David Cook
2	Reason for the notification
a)	Position/status	Non-Executive Chairman, PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alliance Pharma Plc
b)	Legal Entity Identifier	213800RYIWZA4Q5WPZ13
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each GB0031030819
b)	Nature of the transaction	Purchase of shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		77.7p	63,879
e)	Aggregated information - Aggregated volume - Price - Aggregated total	n/a
f)	Date of the transaction	23 June 2020
g)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Katharine Cook
2	Reason for the notification
a)	Position/status	PCA with David Cook, Chairman and PDMR
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Alliance Pharma Plc
b)	Legal Entity Identifier	213800RYIWZA4Q5WPZ13
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each GB0031030819
b)	Nature of the transaction	Purchase of shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		77.7p	63,879
e)	Aggregated information - Aggregated volume - Price - Aggregated total	n/a
f)	Date of the transaction	23 June 2020
g)	Place of the transaction	London Stock Exchange, AIM

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
Numis Securities Limited	+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Huw Jeremy
Corporate Broking: James Black

Investec Bank plc	+ 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website :  www.alliancepharmaceuticals.co m    

 

END

 

 

DSHSEFFWMESSEFM